DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del.--(BUSINESS WIRE)-- ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY ® (datopotamab deruxtecan) demonstrated a statistically significant and ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY ® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically ...
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY®(datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY ...
Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results